Skip to main content

Table 7 Treatment outcomes of FP vs. GP

From: Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

 

FP

GP

P value

Number of patients

83

94

 

RR (%)

24.3

17.6

0.310

DCR (%)

67.6

54.8

0.103

PFS (months)

4.6 (95% CI, 3.5–5.7)

4.3 (95% CI, 3.6–5.0)

0.787

OS (months)

8.1 (95% CI, 7.0–9.3)

8.0 (95% CI, 6.0–10.0)

0.357

  1. F, fluoropyrimidines; P, platinum; G, gemcitabine; RR, response rate; DCR, disease control rate; PFS, progression free survival; CI, confidence interval; OS, overall survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us